Tubular biomarkers to assess progression of diabetic nephropathy.
Level V
Where this comes from
- Record sourced from PubMed, PMID 21527942.
- Also identified by DOI 10.1038/ki.2011.9.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite aggressive management, many patients with diabetic nephropathy still develop end-stage renal disease. Accompanying tubulointerstitial damage is important in the progression of diabetic nephropathy. Markers of tubular damage, such as NGAL, KIM-1, and LFABP, have been proposed for monitoring the effectiveness of therapy. However, Nielsen et al. report a lack of an independent correlation between these biomarkers and glomerular filtration rate. Therefore, these markers seem to offer no improvement in the management of diabetic nephropathy.
Medical subject headings
- Acute-Phase Proteins
- Diabetic Nephropathies
- Fatty Acid-Binding Proteins
- Lipocalins
- Membrane Glycoproteins
- Proto-Oncogene Proteins